BRPI0919447B8 - compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer - Google Patents
compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncerInfo
- Publication number
- BRPI0919447B8 BRPI0919447B8 BRPI0919447A BRPI0919447A BRPI0919447B8 BR PI0919447 B8 BRPI0919447 B8 BR PI0919447B8 BR PI0919447 A BRPI0919447 A BR PI0919447A BR PI0919447 A BRPI0919447 A BR PI0919447A BR PI0919447 B8 BRPI0919447 B8 BR PI0919447B8
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- pharmaceutical composition
- treat cancer
- compounds derived
- cyclobutylethylboronic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- BCNMPHGGRXUKHU-UHFFFAOYSA-N (1-amino-2-cyclobutylethyl)boronic acid Chemical compound OB(O)C(N)CC1CCC1 BCNMPHGGRXUKHU-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
derivados de ácido 1-amino-2-ciclobutiletilborônico. a presente invenção fornece novos compostos úteis como inibidores de proteassoma. a presente invenção também fornece composições farmacêuticasa compreendendo os compostos da invenção e método de usar as composições no tratamento de varias doenças.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19461408P | 2008-09-29 | 2008-09-29 | |
US61/194,614 | 2008-09-29 | ||
PCT/US2009/005324 WO2010036357A1 (en) | 2008-09-29 | 2009-09-25 | Derivatives of 1-amino-2-cyclobutylethylboronic acid |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0919447A2 BRPI0919447A2 (pt) | 2015-12-15 |
BRPI0919447B1 BRPI0919447B1 (pt) | 2021-03-30 |
BRPI0919447B8 true BRPI0919447B8 (pt) | 2021-05-25 |
Family
ID=41426361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919447A BRPI0919447B8 (pt) | 2008-09-29 | 2009-09-25 | compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer |
Country Status (25)
Country | Link |
---|---|
US (3) | US8664200B2 (pt) |
EP (1) | EP2346882B1 (pt) |
JP (3) | JP5736314B2 (pt) |
KR (1) | KR101739470B1 (pt) |
CN (2) | CN103554143B (pt) |
AR (1) | AR075090A1 (pt) |
AU (1) | AU2009297113B2 (pt) |
BR (1) | BRPI0919447B8 (pt) |
CA (1) | CA2739375C (pt) |
CL (1) | CL2011000653A1 (pt) |
CO (1) | CO6362015A2 (pt) |
CR (2) | CR20160475A (pt) |
DO (1) | DOP2011000086A (pt) |
EA (1) | EA030539B1 (pt) |
EC (1) | ECSP11011011A (pt) |
IL (1) | IL211983A0 (pt) |
MA (1) | MA32729B1 (pt) |
MX (1) | MX2011003317A (pt) |
MY (1) | MY166653A (pt) |
NZ (2) | NZ606001A (pt) |
SG (1) | SG194388A1 (pt) |
TW (2) | TWI598352B (pt) |
UA (1) | UA105503C2 (pt) |
WO (1) | WO2010036357A1 (pt) |
ZA (1) | ZA201203615B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687456B2 (en) | 2005-11-09 | 2010-03-30 | Proteolix, Inc. | Compounds for enzyme inhibition |
NZ597545A (en) | 2006-06-19 | 2013-07-26 | Proteolix Inc | Peptide epoxyketones for proteasome inhibition |
EP2207791B2 (en) | 2007-10-04 | 2019-08-07 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
BRPI0915300C1 (pt) | 2008-06-17 | 2021-05-25 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
MX368109B (es) | 2008-10-21 | 2019-09-18 | Onyx Therapeutics Inc | Terapia de combinacion con epoxicetonas peptidicas. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
EP2542238B1 (en) * | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
UA110612C2 (uk) | 2010-03-31 | 2016-01-25 | Мілленніум Фармасьютікалз, Інк. | Похідні 1-аміно-2-циклопропілетилборонової кислоти |
EP2776586B1 (en) | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
WO2013071142A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
CA2860142C (en) | 2011-12-22 | 2020-10-27 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
CN104204797B (zh) | 2012-01-24 | 2017-05-31 | 米伦纽姆医药公司 | 治疗癌症的方法 |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
BR112015012909A2 (pt) * | 2012-12-03 | 2017-07-11 | Hoffmann La Roche | compostos de ácido borônico de triazol substituído |
WO2015051067A1 (en) | 2013-10-03 | 2015-04-09 | Millennium Pharmaceuticals, Inc. | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
USRE49816E1 (en) | 2014-01-10 | 2024-01-30 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
JP2017524652A (ja) | 2014-05-20 | 2017-08-31 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 |
US10301273B2 (en) | 2014-08-07 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
EP3193904A4 (en) | 2014-08-18 | 2018-04-11 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
ES2761774T3 (es) * | 2014-10-01 | 2020-05-21 | Merck Patent Gmbh | Derivados del ácido borónico |
JP6835710B2 (ja) * | 2014-10-01 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ボロン酸誘導体 |
CA2963198A1 (en) * | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
WO2016050359A1 (en) * | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
EP3362754B1 (en) | 2015-10-15 | 2021-12-22 | Cornell University | Proteasome inhibitors and uses thereof |
JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
EP4257191A3 (en) | 2016-06-21 | 2023-11-22 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
WO2018160717A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
DE3827340A1 (de) * | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
ES2098484T3 (es) | 1992-08-14 | 1997-05-01 | Procter & Gamble | Detergentes liquidos que contienen un acido alfa-amino-boronico. |
US5492900A (en) | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
US5935944A (en) | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
JP2001511814A (ja) | 1997-02-15 | 2001-08-14 | プロスクリプト・インコーポレイテッド | NF−κBの阻害を介する梗塞の治療 |
WO1999015183A1 (en) | 1997-09-25 | 1999-04-01 | Proscript Inc. | PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES |
CN1282242A (zh) | 1997-12-16 | 2001-01-31 | 赛福伦公司 | 多相催化蛋白酶抑制剂用作抗肿瘤剂 |
US6169076B1 (en) | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
CA2376965A1 (en) | 1999-07-07 | 2001-01-11 | Timothy Patrick Forsyth | Peptide boronic acid inhibitors of hepatitis c virus protease |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
JP4162491B2 (ja) | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
ES2258149T3 (es) | 2001-05-30 | 2006-08-16 | Novartis Ag | Derivados de acido 2-((n-(2-amino-3-(heteroaril o aril)propionil)aminoacil)amino)alquilboronico. |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
WO2003059898A2 (en) | 2002-01-08 | 2003-07-24 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
WO2003105860A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
UA88771C2 (ru) * | 2003-08-14 | 2009-11-25 | Сефалон, Инк. | Ингибиторы протеасомы и способ их применения (варианты) |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
KR100939598B1 (ko) | 2004-03-30 | 2010-02-01 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 붕소산 에스테르와 산 화합물의 합성 |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
WO2007005991A1 (en) | 2005-07-05 | 2007-01-11 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
WO2007089618A2 (en) | 2006-01-27 | 2007-08-09 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
RS52435B (en) | 2007-08-06 | 2013-02-28 | Millennium Pharmaceuticals Inc. | PROTEAZOMA INHIBITORS |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
BRPI0915300C1 (pt) | 2008-06-17 | 2021-05-25 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
UA110612C2 (uk) | 2010-03-31 | 2016-01-25 | Мілленніум Фармасьютікалз, Інк. | Похідні 1-аміно-2-циклопропілетилборонової кислоти |
-
2009
- 2009-09-12 AR ARP090103760A patent/AR075090A1/es not_active Application Discontinuation
- 2009-09-25 BR BRPI0919447A patent/BRPI0919447B8/pt active IP Right Grant
- 2009-09-25 CN CN201310475757.1A patent/CN103554143B/zh active Active
- 2009-09-25 CN CN200980144074XA patent/CN102203103A/zh active Pending
- 2009-09-25 UA UAA201105450A patent/UA105503C2/uk unknown
- 2009-09-25 AU AU2009297113A patent/AU2009297113B2/en not_active Ceased
- 2009-09-25 SG SG2013073267A patent/SG194388A1/en unknown
- 2009-09-25 WO PCT/US2009/005324 patent/WO2010036357A1/en active Application Filing
- 2009-09-25 NZ NZ606001A patent/NZ606001A/en not_active IP Right Cessation
- 2009-09-25 MY MYPI2011001392A patent/MY166653A/en unknown
- 2009-09-25 EP EP09789372.1A patent/EP2346882B1/en active Active
- 2009-09-25 MX MX2011003317A patent/MX2011003317A/es active IP Right Grant
- 2009-09-25 CA CA2739375A patent/CA2739375C/en active Active
- 2009-09-25 CR CR20160475A patent/CR20160475A/es unknown
- 2009-09-25 KR KR1020117009732A patent/KR101739470B1/ko active IP Right Grant
- 2009-09-25 NZ NZ592497A patent/NZ592497A/xx not_active IP Right Cessation
- 2009-09-25 US US12/586,650 patent/US8664200B2/en active Active
- 2009-09-25 EA EA201170508A patent/EA030539B1/ru not_active IP Right Cessation
- 2009-09-25 JP JP2011529021A patent/JP5736314B2/ja active Active
- 2009-09-29 TW TW105105530A patent/TWI598352B/zh not_active IP Right Cessation
- 2009-09-29 TW TW098133005A patent/TW201024313A/zh unknown
-
2011
- 2011-03-25 CL CL2011000653A patent/CL2011000653A1/es unknown
- 2011-03-28 DO DO2011000086A patent/DOP2011000086A/es unknown
- 2011-03-28 IL IL211983A patent/IL211983A0/en unknown
- 2011-04-26 CR CR20110216A patent/CR20110216A/es unknown
- 2011-04-26 MA MA33796A patent/MA32729B1/fr unknown
- 2011-04-27 CO CO11051428A patent/CO6362015A2/es active IP Right Grant
- 2011-04-28 EC EC2011011011A patent/ECSP11011011A/es unknown
-
2012
- 2012-05-17 ZA ZA2012/03615A patent/ZA201203615B/en unknown
-
2014
- 2014-01-13 US US14/153,752 patent/US9771381B2/en active Active
-
2015
- 2015-04-20 JP JP2015085803A patent/JP2015143264A/ja active Pending
-
2016
- 2016-10-11 JP JP2016199804A patent/JP2017025091A/ja active Pending
-
2017
- 2017-08-18 US US15/680,514 patent/US10035811B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919447B8 (pt) | compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer | |
BRPI0915300C1 (pt) | compostos de éster boronato e composições farmacêuticas dos mesmos | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
EP2321264A4 (en) | DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF | |
BRPI0813499B8 (pt) | compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos | |
MX336381B (es) | Boronatos como inhibidores de arginasa. | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
BR112012007747A2 (pt) | Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
BRPI0916286B8 (pt) | amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica | |
UY31952A (es) | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos | |
ECSP10010494A (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
ECSP088884A (es) | Compuestos heterociclicos fusionados y su uso como moduladores de mglur5 | |
ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
BRPI0909737A2 (pt) | compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
BR112015010196A2 (pt) | métodos de tratar doença do fígado | |
EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
DOP2010000027A (es) | Inhibidores de proteasoma | |
SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |